SCHEMBL5831173

SCHEMBL5831173

CCCc1ccc(S(=O)(=O)Nc2nc(CC(=O)N3CCSCC3)ns2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
AKT1 P31749 3/20 0.41
IRS1 P35568 2/20 0.41
GAB1 Q13480 2/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 1/20 0.41
NAMPT P43490 1/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831153 0.91 HPGD (0.53) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5832372 0.89 TSHR (0.54) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5831433 0.88 ALDH1A1 (0.41) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5831431 0.88 ALDH1A1 (0.41) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5832016 0.85 USP36 (0.44) ALDH1A1MAPTKMT2AMEN1GAA
SCHEMBL3602414 0.84 HSD11B1 (0.49) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5831265 0.83 AKT1 (0.59) ALDH1A1MAPTKMT2AMEN1AKT1
SCHEMBL3251304 0.82 HSD11B1 (0.49) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL6610387 0.80 ALDH1A1 (0.43) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL5832128 0.78 AKT1 (0.47) ALDH1A1AKT1IRS1GAB1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 ALDH1A1 63/4885MAPT 4201/4885HPGD 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.